ARTICLE
22 September 2022

Holland & Knight Health Dose: September 21, 2022

HK
Holland & Knight

Contributor

Holland & Knight is a global law firm with nearly 2,000 lawyers in offices throughout the world. Our attorneys provide representation in litigation, business, real estate, healthcare and governmental law. Interdisciplinary practice groups and industry-based teams provide clients with access to attorneys throughout the firm, regardless of location.
Holland & Knight Health Dose is an in-depth weekly dose of legislative and regulatory insights to keep stakeholders abreast of happenings in Washington, D.C., impacting the health sector.
United States Food, Drugs, Healthcare, Life Sciences

Holland & Knight Health Dose is an in-depth weekly dose of legislative and regulatory insights to keep stakeholders abreast of happenings in Washington, D.C., impacting the health sector.

This week's topics include:

  • Congress This Week: Continuing Budget Resolution Talks Continue
  • House Passes Medicare Advantage Prior Authorization Legislation
  • Reps. Bera, Bucshon Introduce Bill to Thwart Proposed Conversion Factor Cuts
  • Telehealth Action Calls
  • House Republicans Press Biden Administration to Take Action on 42 CFR Part 2
  • House Ways and Means Committee Addresses Healthcare System's Preparation for Climate Crisis
  • Surprise Billing Action Picks Back Up
  • Conflicting Remarks Cause Confusion Over Official End of COVID-19 Public Health Emergency
  • Period 3 Provider Relief Funding Reporting Deadline is Sept. 30
  • White House Releases New Roadmap for Behavioral Health Integration
  • White House Issues Executive Order; Outlines Spending For New Biotech, Biomanufacturing Initiative
  • Hurricane Fiona Tests Puerto Rico Health Infrastructure Resiliency
  • New Reports Indicate Record Levels of Enrollment; Certain Advantages for MA Plans

Read the full Health Dose »

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More